Tao Li, Wang Sheng, Zhao Yang, Wang Ai-Yun, Zhang Lei, Ruan Jun-Shan, Fan Fang-Tian, Liu Yu-Ping, Li Yao, Yue Zhi-Qiang, Qian Wen-Hui, Chen Wen-Xing, Lu Yin
Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Chin J Integr Med. 2016 Oct;22(10):795-800. doi: 10.1007/s11655-015-2405-x. Epub 2016 Jun 29.
Accumulative evidences have underpinned the nature candidates from Chinese medicine (CM), particularly CM served as blood activating and stasis resolving (BASR, Huoxue Huayu in Chinese) by targeting tumor-associated angiogenesis. However, recent experiment research on the therapeutic angiogenesis by BASR-CM attracts wide attention and discussion. This opinion review focused on the underlying link between two indications and anticipated that (1) BASR-CM might emphasize on a balanced multi-cytokines network interaction; (2) BASR-CM might address on the nature of diseases prior to differently affecting physiological and pathological angiogenesis; (3) BASR-CM might mainly act on perivascular cells, either promotes arteriogenesis by increasing arteriogenic factors in ischemic diseases, or simultaneously keep a quiescent vasculature to impede angiogenesis in tumor context.
越来越多的证据支持了来自中药的天然候选物,特别是通过靶向肿瘤相关血管生成发挥活血祛瘀(BASR,中文为活血化瘀)作用的中药。然而,最近关于BASR类中药治疗性血管生成的实验研究引起了广泛关注和讨论。本观点综述聚焦于这两种适应症之间的潜在联系,并预期:(1)BASR类中药可能强调平衡的多细胞因子网络相互作用;(2)BASR类中药可能在不同影响生理和病理血管生成之前先针对疾病本质;(3)BASR类中药可能主要作用于血管周围细胞,在缺血性疾病中通过增加促动脉生成因子促进动脉生成,或在肿瘤环境中同时维持血管静止以阻碍血管生成。